Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer.
CONCLUSIONS: The addition of EGFR MAb to either chemotherapy or best supportive care improves progression-free survival (moderate- to high-quality evidence), overall survival (high-quality evidence), and tumour response rate (moderate- to high-quality evidence), but may increase toxicity in people with KRAS exon 2 wild-type or extended RAS wild-type metastatic colorectal cancer (moderate-quality evidence). The addition of EGFR TKI to standard therapy does not improve clinical outcomes. EGFR MAb combined with bevacizumab is of no clinical value (very low-quality evidence). Future studies should focus on optimal sequencing and predictive biomarkers and collect quality of life data.
PMID: 28654140 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - Category: General Medicine Authors: Chan DLH, Segelov E, Wong RS, Smith A, Herbertson RA, Li BT, Tebbutt N, Price T, Pavlakis N Tags: Cochrane Database Syst Rev Source Type: research
More News: Avastin | Brain | Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Colorectal Cancer | Conferences | Databases & Libraries | Diarrhoea | General Medicine | International Medicine & Public Health | Neuroblastoma | Neurology | PET Scan | Sarcomas | Statistics | Study | Toxicology | WHO